Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies

Bian, Bingxian; Li, Li; Yang, Junyao; Liu, Yi; Xie, Guohua; Zheng, Yingxia; Zeng, Liang; Zeng, Junxiang; Shen, Lisong

doi:10.1186/s12935-019-0983-y

Cited by 30 publications

(36 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous meta-analysis showed that elevated circulating levels of YKL-40 were significantly related to poor survival in cancer patients [7]. Certain studies have examined the prognostic implication of YKL-40 tissue expression in patients with solid tumors, but these studies have yielded inconsistent results [8][9][10][11][12][13][14][26][27][28].…”

Section: Discussionmentioning

confidence: 99%

“…YKL-40 is considered to play a role in cancer through the process of inflammation surrounding the tumor cells, angiogenesis, and extracellular matrix remodeling [5,6]. According to a recent meta-analysis based on 41 cohort studies with 7762 patients, a high YKL-40 serum/plasma level is correlated with a poor prognosis in patients with solid tumors [7]. Previous studies have shown that YKL-40 tissue expression may serve as a useful prognostic biomarker for solid tumors, such as glioma, ovarian cancer, breast cancer, lung cancer, urologic neoplasm, thyroid carcinoma, and gastric cancer [8][9][10][11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer

Pyo

Son

2021

Current Oncology

View full text Add to dashboard Cite

This study aims to examine the clinicopathological and prognostic significance of the YKL-40 immunohistochemical expression of tumor and immune cells through human colorectal cancer (CRC) tissue. We performed immunohistochemistry for YKL-40 and investigated the clinicopathological and prognostic impact of the YKL-40 expression of tumor (T-YKL-40) and immune cells (I-YKL-40) in CRC. We also evaluated the correlation between YKL-40 and PD-L1 expression and the immunoscore. YKL-40 was expressed in 22.6% and 64.2% of T-YKL-40 and I-YKL-40, respectively, out of the 265 CRC tissues. The I-YKL-40 expression significantly correlated with well and moderately differentiated tumors. The PD-L1 expression in immune cells significantly correlated with the I-YKL-40 expression, but not T-YKL-40 expression (p = 0.020 and p = 0.846, respectively). The I-YKL-40 expression significantly correlated with a worse overall survival rate but not recurrence-free survival (p = 0.047 and p = 0.080, respectively). However, there was no significant correlation between the T-YKL-40 expression and survival. In CRCs with a high immunoscore, patients with I-YKL-40 expression demonstrated worse overall and recurrence-free survival than those without I-YKL-40 expression. Our results demonstrated that I-YKL-40 expression significantly correlated with tumor differentiation and PD-L1 expression in immune cells. I-YKL-40 expression can be useful for the prognostic stratification of CRC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer

Pyo

Son

2021

Current Oncology

View full text Add to dashboard Cite

show abstract

“…Chitinase 3 like 1 (YKL-40/CHI3L1) protein is a member of chitinase family. The elevated expression of YKL-40 is observed in many malignant tumors, which drives tumor growth, angiogenesis and metastasis [ 4 , 5 ]. Previous studies suggest that YKL-40 is up-regulated in the serum and endometrial carcinoma samples of EC patients, and correlates with a poor prognosis [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Exosomal lncRNA NEAT1 from cancer-associated fibroblasts facilitates endometrial cancer progression via miR-26a/b-5p-mediated STAT3/YKL-40 signaling pathway

et al. 2021

View full text Add to dashboard Cite

Cancer-associated fibroblasts cells (CAFs) confer a rapid growth and metastasis ability of endometrial cancer (EC) via exosomes-mediated cellular communication. Long non-coding RNA nuclear enriched abundant transcript 1 (lncRNA NEAT1) drives the malignant phenotypes of EC cells. However, the role of exosomal NEAT1 from CAFs in EC progression remains ambiguous, which needs to be investigated. In our study, NEAT1 and YKL-40 were up-regulated, while miR-26a/b-5p was down-regulated in EC tissues. Moreover, NEAT1 expression was increased in CAF-exosomes compared with that in NF-exosomes. In addition, the exosomal NEAT1 derived from CAFs could transfer to EC cells and promote YKL-40 expression. Further exploration showed that exosomal NEAT1 enhanced YKL-40 expression via regulating miR-26a/b-5p-STAT3 axis in EC cells. More importantly, exosomal NEAT1 accelerated in vivo tumor growth via miR-26a/b-5p-STAT3-YKL-40 axis. Taken together, our study reveals that exosomal NEAT1 from CAFs contributes to EC progression via miR-26a/b-5p-mediated STAT3/YKL-40 pathway, which indicates the therapeutic potential of exosomal NEAT1 for treating EC.

show abstract

“…YKL-40 is secreted by tumour cells, such as colon cancer cells, and by tumour-associated macrophages [31], and promotes cancer proliferation and inflammation [32]. Elevated YKL-40 expression in tumours and in the circulation is associated with poor prognosis in various tumour types, including CRC [32][33][34].…”

Section: Introductionmentioning

confidence: 99%

Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer

Lehtomäki

Mustonen

Kellokumpu‐Lehtinen

et al. 2021

Cancers

View full text Add to dashboard Cite

In colorectal cancer (CRC), 20–50% of patients relapse after curative-intent surgery with or without adjuvant therapy. We investigated the lead times and prognostic value of post-adjuvant (8 months from randomisation to adjuvant treatment) serum CEA, CA19-9, IL-6, CRP, and YKL-40. We included 147 radically resected stage II–IV CRC treated with 24 weeks of adjuvant 5-fluorouracil-based chemotherapy in the phase III LIPSYT-study (ISRCTN98405441). All 147 were included in lead time analysis, but 12 relapsing during adjuvant therapy were excluded from post-adjuvant analysis. Elevated post-adjuvant CEA, IL-6, and CRP were associated with impaired disease-free survival (DFS) with hazard ratio (HR) 5.21 (95% confidence interval 2.32–11.69); 3.72 (1.99–6.95); 2.58 (1.18–5.61), respectively, and elevated IL-6 and CRP with impaired overall survival (OS) HR 3.06 (1.64–5.73); 3.41 (1.55–7.49), respectively. Elevated post-adjuvant IL-6 in CEA-normal patients identified a subgroup with impaired DFS. HR 3.12 (1.38–7.04) and OS, HR 3.20 (1.39–7.37). The lead times between the elevated biomarker and radiological relapse were 7.8 months for CEA and 10.0–53.1 months for CA19-9, IL-6, CRP, and YKL-40, and the lead time for the five combined was 27.3 months. Elevated post-adjuvant CEA, IL-6, and CRP were associated with impaired DFS. The lead time was shortest for CEA.

show abstract

Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies

Cited by 30 publications

References 62 publications

Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer

Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer

Exosomal lncRNA NEAT1 from cancer-associated fibroblasts facilitates endometrial cancer progression via miR-26a/b-5p-mediated STAT3/YKL-40 signaling pathway

Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer

Contact Info

Product

Resources

About